000288149 001__ 288149
000288149 005__ 20250731111836.0
000288149 0247_ $$2doi$$a10.1002/ijc.34872
000288149 0247_ $$2pmid$$apmid:38357914
000288149 0247_ $$2ISSN$$a0020-7136
000288149 0247_ $$2ISSN$$a1097-0215
000288149 0247_ $$2altmetric$$aaltmetric:159572907
000288149 037__ $$aDKFZ-2024-00363
000288149 041__ $$aEnglish
000288149 082__ $$a610
000288149 1001_ $$00000-0002-6846-1204$$aRinaldi, Sabina$$b0
000288149 245__ $$aCirculating endogenous sex steroids and risk of differentiated thyroid carcinoma in men and women.
000288149 260__ $$aBognor Regis$$bWiley-Liss$$c2024
000288149 3367_ $$2DRIVER$$aarticle
000288149 3367_ $$2DataCite$$aOutput Types/Journal article
000288149 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713259158_20784
000288149 3367_ $$2BibTeX$$aARTICLE
000288149 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288149 3367_ $$00$$2EndNote$$aJournal Article
000288149 500__ $$a2024 Jun 15;154(12):2064-2074
000288149 520__ $$aThyroid cancer (TC) is substantially more common in women than in men, pointing to a possible role of sex steroid hormones. We investigated the association between circulating sex steroid hormones, sex hormone binding globulin (SHBG) and the risk of differentiated TC in men and women within the European Prospective Investigation into Cancer and nutrition (EPIC) cohort. During follow-up, we identified 333 first primary incident cases of differentiated TC (152 in pre/peri-menopausal women, 111 in post-menopausal women, and 70 in men) and 706 cancer-free controls. Women taking exogenous hormones at blood donation were excluded. Plasma concentrations of testosterone, androstenedione, dehydroepiandrosterone, estradiol, estrone and progesterone (in pre-menopausal women only) were performed using liquid chromatography/mass spectrometry method. SHBG concentrations were measured by immunoassay. Odds ratios (ORs) were estimated using conditional logistic regression models adjusted for possible confounders. No significant associations were observed in men and postmenopausal women, while a borderline significant increase in differentiated TC risk was observed with increasing testosterone (adjusted OR T3 vs T1: 1.68, 95% CI: 0.96-2.92, ptrend = .06) and androstenedione concentrations in pre/perimenopausal women (adjusted OR T3 vs T1: 1.78, 95% CI: 0.96-3.30, ptrend = .06, respectively). A borderline decrease in risk was observed for the highest progesterone/estradiol ratio (adjusted OR T3 vs T1: 0.54, 95% CI: 0.28-1.05, ptrend = .07). Overall, our results do not support a major role of circulating sex steroids in the etiology of differentiated TC in post-menopausal women and men but may suggest an involvement of altered sex steroid production in pre-menopausal women.
000288149 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000288149 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288149 650_7 $$2Other$$adifferentiated thyroid cancer
000288149 650_7 $$2Other$$aprospective study
000288149 650_7 $$2Other$$asex steroids
000288149 7001_ $$aDossus, Laure$$b1
000288149 7001_ $$aKeski-Rahkonen, Pekka$$b2
000288149 7001_ $$aKiss, Agneta$$b3
000288149 7001_ $$aNavionis, Anne-Sophie$$b4
000288149 7001_ $$aBiessy, Carine$$b5
000288149 7001_ $$aTravis, Ruth$$b6
000288149 7001_ $$aWeiderpass, Elisabete$$b7
000288149 7001_ $$aRomieu, Isabelle$$b8
000288149 7001_ $$aEriksen, Anne Kirstine$$b9
000288149 7001_ $$aTjonneland, Anne$$b10
000288149 7001_ $$00000-0002-4557-3772$$aKvaskoff, Marina$$b11
000288149 7001_ $$aCanonico, Marianne$$b12
000288149 7001_ $$00000-0002-2943-6786$$aTruong, Thérèse$$b13
000288149 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b14$$udkfz
000288149 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b15$$udkfz
000288149 7001_ $$00000-0003-2597-2060$$aCatalano, Alberto$$b16
000288149 7001_ $$aPanico, Salvatore$$b17
000288149 7001_ $$aMasala, Giovanna$$b18
000288149 7001_ $$aTumino, Rosario$$b19
000288149 7001_ $$00000-0002-3608-9743$$aLukic, Marko$$b20
000288149 7001_ $$aOlsen, Karina Standahl$$b21
000288149 7001_ $$00000-0002-6236-6804$$aZamora-Ros, Raul$$b22
000288149 7001_ $$aSantiuste, Carmen$$b23
000288149 7001_ $$aAizpurua Atxega, Amaia$$b24
000288149 7001_ $$aGuevara, Marcela$$b25
000288149 7001_ $$aRodriguez-Barranco, Miguel$$b26
000288149 7001_ $$aSandstrom, Maria$$b27
000288149 7001_ $$aHennings, Joakim$$b28
000288149 7001_ $$aAlmquist, Martin$$b29
000288149 7001_ $$aAglago Kouassivi, Elom$$b30
000288149 7001_ $$00000-0001-9219-4436$$aChristakoudi, Sofia$$b31
000288149 7001_ $$aGunter, Marc$$b32
000288149 7001_ $$aFranceschi, Silvia$$b33
000288149 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34872$$gp. ijc.34872$$n12$$p2064-2074$$tInternational journal of cancer$$v154$$x0020-7136$$y2024
000288149 8564_ $$uhttps://inrepo02.dkfz.de/record/288149/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Rinaldi%20-%20Circulating%20endogenous%20sex%20steroids%20and%20risk%20of%20differentiated%20thyroid%20carcinoma.pdf
000288149 8564_ $$uhttps://inrepo02.dkfz.de/record/288149/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Rinaldi%20-%20Circulating%20endogenous%20sex%20steroids%20and%20risk%20of%20differentiated%20thyroid%20carcinoma.pdf?subformat=pdfa$$xpdfa
000288149 909CO $$ooai:inrepo02.dkfz.de:288149$$pVDB
000288149 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000288149 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000288149 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000288149 9141_ $$y2024
000288149 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000288149 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000288149 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000288149 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000288149 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000288149 980__ $$ajournal
000288149 980__ $$aVDB
000288149 980__ $$aI:(DE-He78)C020-20160331
000288149 980__ $$aUNRESTRICTED